Skip to main content

Table 5 IPDASi (probabilities) and development process ratings for tools

From: A review of decision support, risk communication and patient information tools for thrombolytic treatment in acute stroke: lessons for tool developers

 

IPDASi (Probabilities) items [12]

Development process items

 

1 n (%)

2 n (%)

3 n (%)

4 n (%)

5 n (%)

6 n (%)

7 n (%)

8 n (%)

Median (IQR) probabilities total

1 n (%)

2 n (%)

3 n (%)

4 n (%)

5 n (%)

6

n (%)

RCT

5 (100)

5 (100)

5 (100)

2 (40)

2 (40)

1 (20)

4 (80)

5 (100)

5 (3)

3 (60)

1 (20)

0 (0)

1 (20)

1

(20)

0 (0)

PIT

17 (100)

17 (100)

13 (77)

6 (36)

2 (12)

1 (6)

6 (36)

3 (18)

4 (1.5)

8 (47)

1 (6)

0 (0)

2 (12)

3 (18)

0 (0)

BDA

2 (67)

2 (67)

0 (0)

2 (67)

2 (67)

1 (33)

1 (33)

0 (0)

4 (0)

3 (100)

1 (33)

0 (0)

0 (0)

0 (0)

0 (0)

SI

1 (100)

1 (100)

1 (100)

0 (0)

1 (100)

0 (0)

0 (0)

0 (0)

4 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

Overall

25 (96)

25 (96)

19 (73)

10 (39)

7 (27)

3 (12)

11 (42)

8 (31)

4 (2)

14 (54)

3 (12)

0 (0)

3 (12)

4 (15)

0 (0)

  1. RCT = Risk communication tool PIT = Patient information tool BDA = Brief decision aid SI = Standardised information.
  2. IPDASi (Probabilities) items: [12].
  3. 1 = provides information about outcome probabilities (OPs) associated with the options; 2 = specifies defined group (reference class) of patients for which the OPs apply; 3 = specifies the event rates for OPs (in natural frequencies); 4 = specifies time period over which the OPs apply; 5 = allows the user to compare OPs across options using the same denominator and time period; 6 = provides information about the levels of uncertainty around event/OPs; 7 = provides more than one way of viewing the probabilities; 8 = provides balanced information about event or OPs to limit framing biases.
  4. Development process items:
  5. 1 = evidence that developers have considered best available evidence; 2 = intervention based on an established theory/body of evidence; 3 = elicitation study on risk/benefit information required by patients/families or clinicians; 4 = tool subjected to ‘testing’ in patients and families or clinicians; 5 = development of tool guided by steering group; 5 = tool subjected to exploratory trial.